Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 7/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.39 |
| ▸ | AXL | P30530 | 3/20 | 0.37 |
| ▸ | FLT3 | P36888 | 3/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.37 |
| ▸ | MERTK | Q12866 | 3/20 | 0.37 |
| ▸ | WNT1 | P04628 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4366602 | 0.92 | ALK (0.59) | ALKJAK2MAPK1 | |
| SCHEMBL13633028 | 0.90 | ALK (0.43) | ALKJAK2AXLFLT3TYRO3 | |
| SCHEMBL13632968 | 0.89 | ALK (0.42) | ALKJAK2 | |
| SCHEMBL13633046 | 0.88 | ALK (0.44) | ALKJAK2 | |
| SCHEMBL13633060 | 0.88 | ALK (0.41) | ALKJAK2CCNA2CDK2 | |
| Trifluoroacetic Acid SCHEMBL4358301 | 0.87 | ALK (0.54) | ALKJAK2MAPK1 | |
| SCHEMBL13634089 | 0.86 | KDM5A (0.40) | ALKJAK2 | |
| SCHEMBL13633084 | 0.85 | ALK (0.41) | ALKJAK2MAPK1AXLFLT3 | |
| SCHEMBL13632895 | 0.85 | ALK (0.39) | ALKJAK2AXLFLT3TYRO3 | |
| SCHEMBL13633062 | 0.85 | FASN (0.43) | ALKCCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | ALK 3/4885JAK2 1/4885MAPK1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.